The total number of records retrieved from this search are 24. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_935	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_936	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_937	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_938	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro result90% cancer cell survive after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_967	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result90% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_968	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result90% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_969	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result90% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_970	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro result80% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1023	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result100% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1024	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result100% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1025	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result100% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1026	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result70% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1027	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result100% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1028	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result80% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1029	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result75% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1030	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result10% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1031	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result80% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1032	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result50% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1033	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result30% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1034	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell killing after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1035	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result50% cell survival after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1036	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result100% cell killing after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1037	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result100% cell killing after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1038	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-79	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell killing after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577